Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
March 24, 2021 at 04:04 pm EDT
Share
Genovate Biotechnology Co., Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was TWD 472.723 million compared to TWD 465.756 million a year ago. Operating income was TWD 39.497 million compared to TWD 39.477 million a year ago. Net income was TWD 38.731 million compared to TWD 34.055 million a year ago. Basic earnings per share was TWD 0.37 compared to TWD 0.32 a year ago.
Genovate Biotechnology Co., LTD. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of pharmaceutical preparations, drug substances and intermediates. The Company's products include nervous system drugs, digestive system drugs, analgesic and anti-inflammatory drugs, urogenital system drugs, antimicrobial drugs, cardiovascular system drugs, acne drugs, antineoplastic drugs and anti-diabetic drugs, as well as healthcare food and cosmetics. The Company is also engaged in the provision of clinical experimental testing services and technology export services. The Company distributes its products mainly within domestic market.
GENOVATE BIOTECHNOLOGY CO., LTD. 
